Mantle cell lymphoma diagnostic study of choice: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 12: | Line 12: | ||
* The microscopic histological findings can be found [[Mantle cell lymphoma pathophysiology #Microscopic Pathology|'''here''']]. | * The microscopic histological findings can be found [[Mantle cell lymphoma pathophysiology #Microscopic Pathology|'''here''']]. | ||
==== Immunohistochemistry: ==== | ==== Immunohistochemistry: ====<ref>{{Cite journal | ||
* CD19, CD20, CD22, CD43, CD79a, CD5, and FMC7 typically are positive, whereas CD23, CD10, CD200, and BCL6 | | author = [[Francesco Bertoni]], [[Emanuele Zucca]] & [[Finbarr E. Cotter]] | ||
* | | title = Molecular basis of mantle cell lymphoma | ||
* SOX11 expression may be useful if cyclin D1 is negative | | journal = [[British journal of haematology]] | ||
| volume = 124 | |||
| issue = 2 | |||
| pages = 130–140 | |||
| year = 2004 | |||
| month = January | |||
| pmid = 14687022 | |||
}}</ref><ref>{{Cite journal | |||
| author = [[Chan Yoon Cheah]], [[John F. Seymour]] & [[Michael L. Wang]] | |||
| title = Mantle Cell Lymphoma | |||
| journal = [[Journal of clinical oncology : official journal of the American Society of Clinical Oncology]] | |||
| volume = 34 | |||
| issue = 11 | |||
| pages = 1256–1269 | |||
| year = 2016 | |||
| month = April | |||
| doi = 10.1200/JCO.2015.63.5904 | |||
| pmid = 26755518 | |||
}}</ref> | |||
* CD19, CD20, CD22, CD43, CD79a, CD5, and FMC7 typically are positive, whereas CD23, CD10, CD200, and BCL6 are usually negative. | |||
* Cyclin D1 is positive in majority of the cases. | |||
* SOX11 expression may be useful if cyclin D1 is negative. | |||
* | * | ||
Revision as of 20:41, 13 December 2018
|
Mantle cell lymphoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Mantle cell lymphoma diagnostic study of choice On the Web |
|
American Roentgen Ray Society Images of Mantle cell lymphoma diagnostic study of choice |
|
Risk calculators and risk factors for Mantle cell lymphoma diagnostic study of choice |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ali Akram, M.B.B.S.[2]
Overview
Diagnostic Study of Choice
Study of choice
- Tissue biopsy (nodal or extranodal) is the gold standard test for the diagnosis of mantle cell lymphoma.
Histology:
- The microscopic histological findings can be found here.
==== Immunohistochemistry: ====[1][2]
- CD19, CD20, CD22, CD43, CD79a, CD5, and FMC7 typically are positive, whereas CD23, CD10, CD200, and BCL6 are usually negative.
- Cyclin D1 is positive in majority of the cases.
- SOX11 expression may be useful if cyclin D1 is negative.
References
- ↑ Francesco Bertoni, Emanuele Zucca & Finbarr E. Cotter (2004). "Molecular basis of mantle cell lymphoma". British journal of haematology. 124 (2): 130–140. PMID 14687022. Unknown parameter
|month=ignored (help) - ↑ Chan Yoon Cheah, John F. Seymour & Michael L. Wang (2016). "Mantle Cell Lymphoma". Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34 (11): 1256–1269. doi:10.1200/JCO.2015.63.5904. PMID 26755518. Unknown parameter
|month=ignored (help)